|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sprague-Dawley rats were subjected to a middle cerebral artery occlusion (MCAO) model of ischemic stroke, and then were either administered rtPA, rtPA combined with IM-12, or the vehicle at 4 h after stroke was induced.
|
31770017 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
ProTα administration at 2 and 4.5 h after MCAO significantly inhibited tPA (4.5 h)-induced motor dysfunction and death more than 7 days.
|
31454420 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further found that the expression of Arg-1 was also upregulated in those tPA and RSG-treated stroke mice and the protection against tPA-induced HT and BBB disruption in these mice were abolished in the presence of PPAR-γ antagonist GW9662 (4 mg/kg, 1 hour before dMCAO through intraperitoneal injection).
|
31756041 |
2019 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
|
30074208 |
2018 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we developed a new strategy by incorporating tPA into porous magnetic iron oxide (Fe<sub>3</sub>O<sub>4</sub>)-microrods (tPA-MRs) for targeted thrombolytic therapy in ischemic stroke induced by distal middle cerebral artery occlusion.
|
30192506 |
2018 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adult CST-YFP mice were subjected to right unilateral middle cerebral artery occlusion (MCAo), and were randomly divided into groups treated with saline or tPA intranasally in the subacute phase.
|
29518364 |
2018 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Delayed t-PA infusion significantly increased the mortality rate, induced HT, blood-brain barrier (BBB) damage, and apoptotic cell death in the ischemic brains and exacerbated neurological outcomes in cerebral ischemia-reperfusion rats at 24 h after MCAO cerebral ischemia.
|
29275501 |
2018 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, co-administration of Fasudil-Lip and t-PA after 3 h occlusion, beyond the TTW of t-PA in MCAO rats, significantly suppressed brain cell damage compared with t-PA treatment alone.
|
29162447 |
2018 |
|
C20orf181
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a multimodal CT protocol (non-contrast CT, PCT, CT angiography) to prospectively study patients with middle cerebral artery occlusion treated with tPA within 4.5 hours of symptom onset.
|
29182658 |
2017 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bone-marrow transplantation studies indicate that resident CD11b<sup>+</sup> cells, but not bone-marrow-derived leukocytes, mediate the early activation of PDGF-CC by tPA after MCAO.
|
28725968 |
2017 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, both PPK and FXII deficiency are protective against intracerebral hemorrhage caused by tissue plasminogen activator-mediated thrombolytic therapy in mice with thrombotic middle cerebral artery occlusion.
|
28824910 |
2017 |
|
C20orf181
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using a rat transient middle cerebral artery occlusion model, we showed that mRNA and protein expression of A2bR increased to a greater extent after ischemia-reperfusion than did expression of the other three adenosine receptors (A1, A2a, and A3). tPA administration reduced A2bR expression in ischemic brain microvessels.
|
28830843 |
2017 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
These adverse effects of tPA were ameliorated in PPK (Klkb1)-deficient and FXII-deficient mice and in wild-type (WT) mice pretreated with a PKal inhibitor prior to tPA. tPA-induced brain hemisphere reperfusion after photothrombolic middle cerebral artery occlusion was increased in Klkb1<sup>-/-</sup> mice compared with WT mice.
|
28130211 |
2017 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.
|
28059661 |
2017 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Middle cerebral artery occlusion (MCAO) was achieved in CD1 mice by introducing a filament to the left MCA for 5 h. When the filament was removed for reperfusion, tPA was infused via the tail vein.A single dose of NMN was injected i.p.(300 mg·kg<sup>-1</sup> ).
|
28812311 |
2017 |
|
C20orf181
|
0.100 |
Biomarker
|
disease |
BEFREE |
Vehicle, recombinant WE, or tissue plasminogen activator was administered during middle cerebral artery occlusion or 2 hours after middle cerebral artery occlusion.
|
21512172 |
2011 |
|
C20orf181
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vivo, administration of MSCs to mice subjected to middle cerebral artery occlusion (MCAo) significantly increased activation of tPA and downregulated PAI-1 levels in the ischemic boundary zone (IBZ) compared with control PBS treated mice, concurrently with increases of myelinated axons and synaptophysin.
|
20140248 |
2010 |